Member Info for The_Paladin

A pre-consolidation share price of 1p would take us to 10p once the 1:10 consolidation is achieved.

As far as I can see, TEB is paid from the annual £250K cash raise, accompanied by share price dilution. MS is not. His salary, and those of the small IB team in Wisconsin are probably derived from company profits. semantic attempts to justify the CEO's contribution in terms of the RNSs issued by the company. How many of these in recent years have resulted in a long lasting increase in the company's MCap?

As previously stated, the primary reason of my investment was a strong belief in the potential value of the company's technology. It would be reassuring to see steps being taken to achieve that value. A name change to the London listing, and a reformatted website may be an attempt to justify the roles of certain senior individuals within the company? I don't perceive any of it as having moved the company forward. Quite the reverse - as demonstrated by the 3 month share price graph. Far worse when one considers the net share price decline since late January 2025.

The company's USP has enormous unrealised potential if we accept everything that is communicated about IB's imaging technology. Unfortunately, the IB team have not yet been able to generate any significant sales of their products, despite their best efforts including displaying their technology on the platforms of larger companies. The company's website offers a summary of their products' capabilities, and interested parties could contact them directly for further information, demonstrations, and discussions.

I regularly read about micro companies with innovative products, and at an early stage in their growth trajectory being bought out for significant sums.

£50m is a low ball sum in the scheme of things but would be worth approximately 20p per share for all investors. Personally, I would settle for half that amount to release sufficient funds for a sizeable investment elsewhere.

Surely MS and his team would welcome the opportunity to be part of a larger company with vastly improved resources to further develop and test their products? Why is the company treading water, when the potential exists for them to do so much more? What is preventing them from selling the potential of the company's technology to a large entity, who would know precisely what to do with it?

I would be interested in what other forum contributors think about this ?

Yet another X message from IBAI proclaiming the superiority of their imaging technology. Why isn't this reflected in their sales? The best outcome for investors would be for IB to seek an outright buyer, who has the wherewithal to take this technology to a worldwide market? Surely this would be a win-win for everyone concerned? Are TEB et al actually pursuing this? Or are they just sitting on their hands, and taking a chunky annual salary with no discernible progress being made by the company?

I am resigned to the fact that IB is proving to be another failed investment. No one outside the Wisconsin bubble is enthusing about the company’s so called “market leading” products. As for the Phase 1 GaM trial, it has been in operation since early 2022. No information has emerged since then to increase the company’s value.

It appears that the selloff of the TEB family shareholding was the beginning of the company’s demise! It has been all downhill since then.

IB seems to be manned by a small team of high quality individuals. Their products are probably as good as they claim. It may well be the fact that their competitors have far superior marketing and sales capabilities - to the extent that IB’s revenues are negligible in the overall marketplace?

Similarly, progress with the GaM trial has been painfully slow, although this is not unusual for a clinical trial.

Should nothing be achieved by early next year, and TEB sets up yet another £250K cash raise, presumably to pay directors’ salaries, then we may assume that we have been sold a dummy. By then, presumably the share price will be lower than the all time low levels at which the company is currently trading?

With apologies to all for such a pessimistic outlook. It is fair to say that the company has achieved nothing concrete to improve investors’ prospects for several years. It would be good to be proved wrong about all this, but there is little evidence to contradict my pessimism.

The 64 trades indicated above until recently were yesterday’s trades. The final trade was an UT @ 0.675p. The share price seems to have been reset to 0.65p this morning, hence the indicated drop in share price.

I will stick with my recent comments. This company has done nothing whatsoever to benefit its shareholders all year! The share price stands at c. 33% of its value at the start of the year, due to the company’s inaction. The cash raise in the early part of the year was mostly to pay directors’ salaries. The share issue accompanying it contributed to the share price dilution we have suffered this year.

64 trades? These are not displayed on the London Stock Exchange website? -0.025p/- 3.7%

Are these delayed trades? If so, there must be a significant number of net sells to reduce the share price by another 0.025p this morning.

It would be good if shareholders heard something meaningful from this company - something that would impact positively on the share price for once!

The revised website, about which I received a LinkedIn message notification this morning, has not yet had the impact that I was hoping for. Four sells so far today including a 0.645p UT just after 08:00. I am forming the opinion that IB is receiving very little recognition outside the Wisconsin bubble? The next anticipated notification is a GaM trial update in December or early next year? The wheels really are grinding very slowly.

Semantic recently added to my investment lexography with the term “c*ckroach” to describe a resilient company under difficult market conditions.

Today we saw the return of the recurring “stale bull. Having thought I understood the meaning of this term, I sought a more precise definition.

https://profitloss.org/dictionary/S/Stale

It quickly occurred to me that most long term IBAI (latterly IQ-AI) investors fall in this category. I would welcome some positive actions from the BOD at least to restore my investment to a break even point. There is little joy in being a persistent stale bull.

Tyke. Yesterday's "rise" at close of trading was effected by a single uncrossing trade (UT). The same happened earlier in the week when the UT value of 0.58p was quoted as the closing share price. Both prices reverted to pre UT values when the market reopened on the following day.

https://www.stockopedia.com/learn/our-data/london-stock-exchange-quotes-463298/

Correct Tyke. It is verbatim C&P information from an RNS, presented as a (paid for) statement on an investor website. Other small companies do the same to proliferate their message.

Tyke,

The last notification from TEB was on Aug 13, 2025 in a succinct statement on the Proactive Investors website, paid for by IB:

"Imaging Biometrics sees improving market conditions: Imaging Biometrics Ltd (LSE:IBAI, OTCQB:IQAIF) chief executive Trevor Brown told investors that conditions are beginning to improve, as the company advances its technologies and also gains traction in its sector.

The company, previously known as IQ-AI, is developing and rolling out solutions to improve outcomes for patients suffering aggressive cancer, on Wednesday reported interim results for the six twelve months ended 31 December.

“Our continued growth and product deployments are making a tangible, life-changing impact on patients who need them most,” Trevor Brown said.

“The board is acutely aware that shareholders (including insiders) have had to exercise great patience over past years as commercialization and acceptance of our cutting-edge technologies has been slower than we had expected.

“The innate conservatism of our market, which serves primarily to protect patients, is also a headwind for the acceptance of innovation. We believe that these conditions are... http://dlvr.it/TMSky3 "

When max drew our attention to the acquisition of icometrix, a small unlisted imaging company, by GE Healthcare Technologies Inc, I checked on their website. I thought that IB might benefit from modifying our website to a similar format to make essential information more accessible to clinicians and investors.. IB have done just that with our website upgrade, from which I effortlessly revisited key IB information yesterday evening.

https://imagingbiometrics.com

Meanwhile, the icometrix website has also been updated to achieve a cool new look.

https://www.icometrix.com

Thank you Tyke,

I gauge progress by an increase in a company’s share price. The information conveyed by IB throughout this year has not added value. The reverse is true, and as stated previously the share price is currently at around 37% of its Jan 2025 level. When and if it recovers to a price in excess of 2p, only then will I discern the start of a recovery. As things stand, the company isn’t offering any tangible benefit to its investors.

Five minutes ago, the market would buy 1m shares @ 0.6766p. My broker is also valuing my shares at this price.

As an investor, who bases my investment on fact, and not on the “hype” surrounding IB’s products and the GaM trial, I see no discernible progress yet.

Progress may yet follow, but nothing of value to investors has emerged from the company all year!

GLA.

Good morning. I just wanted to add that it was well worth reading the article focused on the possible future of AI in this week’s edition of The Economist. It serves to inform and add perspective. GLA

There is no real substance in today's rise as far as I can see. Yesterday's closing price was due to a single UT @ 0.58p at the close of trading. There is no financial data to underpin the (short term, as I see it) interest in IB. There have been many substantial sells, and the share price is currently situated at its value when the company announced its name change. I should add that it is at 37.5% of its value at the end of January 2025.

As an investor, I want to see substantial growth in the sales of the company's own allegedly market leading technology. Why is the company acting as an intermediary in selling a fellow minnow's technology, when it can't sell its own? What about the GaM trial? Our hopes were raised on many fronts through several RNSs concerning the trial. Over three years later, we are still awaiting a positive announcement. We haven't been given any time line other than the trial is due to end in Dec 2025. Investors don't even have the faintest idea of where the company intends to take it? We aren't even clear as to the company's stake in the trial?

I just hope that the next "development" isn't a cash raise to take our recent "partnership" forward? Surely not?

Showjumper. I thought the same as you when I read the announcement. MS et al really are sweating the small stuff if they think that information merited an RNS? 404x’s metaphor describes it perfectly.

What about an RNS concerning the sales of IB’s market leading products, or about progress towards resubmitting the amended analysed Ph1 trial data? Surely these must be IB’s priorities?

Despite all the ongoing LinkedIn messages over several years from the company proclaiming the superior quality of our technology, there is no evidence to support this in the investment world?

Likewise with the GaM trial. With all the required data for resubmission to the FDA in place, following the trial’s soft close, there is no evidence of any progress with the latter?

A worst case scenario has started to occur to me regarding IB? Is there a genuine investment case here? Or is IB a tiny “life-style “ company which exists solely for the material benefit of its employees and directors?

The following extract informs us about the GaM preparation used in MCW’s GliB Ph 1 trial. It was further “developed” and tested at MCW. We are not told whether it is the same as the original preparation, which was patented elsewhere?

This was the reason for my previous question about the “stakeholders”, in addition to IB, with an interest in MCW’s trial? If anyone has further information about this I would be grateful if it could be shared on this forum.

“The treatment evolved from years of research led by Christopher Chitambar, MD, and his lab to study iron-dependent processes in cancer biology and the mechanisms by which gallium compounds target iron metabolism and block malignant cell growth. In preclinical studies, Drs. Chitambar and Kathleen Schmainda, PhD, discovered that gallium maltolate (GaM) significantly slowed the growth, and reduced the size, of glioblastoma.

GaM, originally developed by Harvard and Stanford educated scientist Lawrence R. Bernstein, PhD, is an orally available form of the metal gallium, which, in the body, shares many chemical properties with the highly oxidized form of iron, called Fe(III). Numerous studies examining the relationship between iron and cancer show that increased levels of iron in the body can be associated with increased cancer risk and severity, because cancer cells depend on iron to multiply and spread. Because of gallium’s similarity to Fe(III), it enters cancer cells instead of iron, preventing their multiplication.

“The discovery that GaM has anticancer activity against glioblastoma in pre-clinical studies is extremely exciting; it opens the door for developing it as a drug for treatment of glioblastoma in patients,” says Christopher Chitambar, MD, Emeritus Professor of Medicine and Biophysics, at MCW. “The anticancer mechanism of GaM applies to other solid tumors as well,”